Literature DB >> 12412881

Reversible brain lesions in childhood hypertension.

P Singhi1, C Subramanian, V Jain, S Singhi, M Ray.   

Abstract

UNLABELLED: Posterior leukoencephalopathy syndrome is characterized by an acute, usually reversible, encephalopathy with transient occipital lobe abnormalities detected on MRI that occur mostly in association with acute hypertension. The clinical presentation includes seizures, headache, altered mental status and blindness. Disturbed autoregulation of cerebral blood flow and endothelial injury are central to the pathogenesis of this disorder. Prompt control of hypertension results in rapid and complete neurological recovery. In this report we discuss the cases of two children with acute onset hypertension of different aetiologies that presented with the characteristic features of posterior leukoencephalopathy syndrome.
CONCLUSION: Early recognition of this readily treatable condition may obviate the need for extensive and invasive investigations. Despite the alarming lesions on the MRI, prompt control of hypertension carries a uniformly favourable prognosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412881     DOI: 10.1080/080352502760272740

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  3 in total

1.  Reversible posterior leucoencephalopathy syndrome: a cause of temporary cortical blindness.

Authors:  N Niyadurupola; C A M Burnett; L E Allen
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

Review 2.  Posterior reversible encephalopathy syndrome in a child with steroid-resistant nephrotic syndrome: a case report and review of literature.

Authors:  Yu Zhang; Jianhua Zhou; Yu Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Posterior Reversible Encephalopathy Syndrome in Pediatric Cancer: Clinical and Radiologic Findings.

Authors:  Saadiya Javed Khan; Arjumand Ali Arshad; Mohammad Bilal Fayyaz; Islah Ud Din Mirza
Journal:  J Glob Oncol       Date:  2017-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.